Corrigendum to "Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114" [J. Mol. Biol. 363 (2006) 161-173] (DOI:10.1016/j.jmb.2006.08.007);Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114

Journal of Molecular Biology

Volumn 363, Issue 1, 2006, Pages 161-173

  Kovalevsky, Andrey Y ^a   Liu, Fengling ^a   Leshchenko, Sofiya ^b   Ghosh, Arun K ^b   Louis, John M ^c   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

allosteric binding site; darunavir; drug resistance; HIV 1 protease; ultra high resolution crystal structure

Indexed keywords

DARUNAVIR; DIMER; NITROGEN; PROTEINASE; PROTEINASE INHIBITOR; SULFONAMIDE;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DIASTEREOISOMER; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; ENANTIOMER; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS RESISTANCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748955158     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.08.099     Document Type: Erratum

References (37)

1. De Clercq E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 48 (2005) 1-17
2. Barlett J.A., DeMasi R., Quinn J., Moxham C., and Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15 (2001) 1369-1377
3. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Meibohm A., Condra J.H., et al. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133 (2000) 35-39
4. Wlodawer A., and Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27 (1998) 249-284
5. Hertogs K., Bloor S., Kemp S.D., Van den Eynde C., Alcorn T.M., Pauwels R., et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14 (2000) 1203-1210
6. Wu T.D., Schiffer C.A., Gonzalez M.J., Taylor J., Kantor R., Chou S., et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77 (2003) 4836-4847
7. Ohtaka H., and Freire E. Adaptive inhibitors of the HIV-1 protease. Prog. Biophys. Mol. Biol. 88 (2005) 193-208
8. Ghosh A.K., Kincaid J.F., Cho W., Walters D.E., Krishnan K., Hussain K.A., et al. Potent HIV protease inhibitors incorporating high affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Letters 8 (1998) 687-690
9. Koh Y., Nakata H., Maeda K., Ogata H., Bilcer G., Devasamudram T., et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) TMC-114 (UIC-94017) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
10. De Meyer S., Azijin H., Surleraux D., Jochmans D., Tahri A., Pauwels R., Wigerinck P., and de Bethune M.-P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 2314-2321
11. Tie Y., Boross P., Wang Y.-F., Gaddis L., Hussain A.K., Leshchenko S., et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 338 (2004) 341-352
12. King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Wigerinck P., de Bethune M.-P., and Schiffer C.A. Structural and thermodynamic basis for the binding of TMC-114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78 (2004) 12012-12021
13. Nivesanond K., Peeters A., Lamoen D., and van Alsenoy C. Ab initio calculation of the interaction energy in the P2 binding pocket of HIV-1 protease. Int. J. Quant. Chem. 105 (2005) 292-299
14. Kovalevsky A.Y., Tie Y., Liu F., Boross P., Wang Y.-F., Leshchenko S., et al. Effectiveness of nonpeptidic clinical inhibitor TMC114 to highly drug resistant mutations D30N, I50V, L90M of HIV-1 protease. J. Med. Chem. 49 (2006) 1379-1387
15. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Topics HIV Med. 13 (2005) 125-131
16. Tie Y., Boross P.I., Wang Y.-F., Gaddis L., Liu F., Chen X., et al. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 272 (2005) 5265-5277
17. Shao W., Everitt L., Manchester M., Loeb D.D., Hutchison III C.A., and Swanstrom R. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl Acad. Sci. USA 94 (1997) 2243-2248
18. Surleraux D.L.N.G., Tahri A., Verschueren W.G., Pille G.M.E., de Kock H.A., Jonckers T.H.M., et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48 (2005) 1813-1822
19. Sarkhel S., and Desiraju G.R. N-H...O, O-H...O, and C-H...O hydrogen bonds in protein-ligand complexes: strong and weak interactions in molecular recognition. Proteins: Struct. Funct. Bioinf. 54 (2004) 246-259
20. Desiraju G., and Steiner T. The Weak Hydrogen Bond in Structural Chemistry and Biology (2001), Oxford University Press, Oxford, NY
21. Nishio M., Hirota M., and Umezawa Y. The C-H/π Interaction. Evidence, Nature, and Consequences (1998), Wiley-VCH, New York, NY
22. Rowley R.L., and Pakkanen T. Determination of a methane intermolecular potential model for use in molecular simulations from ab initio calculations. J. Chem. Phys. 110 (1999) 3368-3377
23. Mahalingam B., Wang Y.-F., Boross P., Tozser J., Louis J.M., Harrison R.W., and Weber I.T. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur. J. Biochem. 271 (2004) 1516-1524
24. Tian G., Ghanekar S.V., Aharony D., Shenvi A.B., Jacobs R.T., Liu X., and Greenberg B.D. The mechanism of γ-secretase. Multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J. Biol. Chem. 278 (2003) 28968-28975
25. Sperka T., Pitlik J., Bagossi P., and Tözser J. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorg. Med. Chem. Letters 15 (2005) 3086-3090
26. Judd D.A., Nettles J.H., Nevins N., Snyder J.P., Liotta D.C., Tang J., et al. Polyoxometalate HIV-1 protease inhibitors: a new mode of protease inhibition. J. Am. Chem. Soc. 123 (2001) 886-897
27. Brynda J., Rezacova P., Fabry M., Horejsi M., Stouracova R., Soucek M., et al. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Acta Crystallog. sect. D 60 (2004) 1943-1948
28. Louis J.M., Clore G.M., and Gronenborn A.M. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nature Struct. Biol. 6 (1999) 868-875
29. Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J., Wang Y.-F., et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263 (1999) 238-245
30. Maibaum J., and Rich D.H. Inhibition of porcine pepsin by two substrate analogues containing statine: the effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. J. Med. Chem. 31 (1988) 625-629
31. Otwinowski Z., and Minor W. Processing of X-ray diffraction data in oscillation mode. Methods Enzymol. 276 (1997) 307-326
32. Collaborative Computational Project, Number 4. The CCP4 Suite: programs for protein crystallography. Acta Crystallog. sect. D 50 (1994) 760-763
33. Potterton E., Briggs P., Turkenburg M., and Dodson E.A. Graphical user interface to the CCP4 program suite. Acta Crystallog. sect. D 59 (2003) 1131-1137
34. Sheldrick G.M., and Schneider T.R. High resolution refinement. Methods Enzymol. 277 (1997) 319-343
35. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A 47 (1991) 110-119
36. Esnouf R.M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallog. sect. D 55 (1999) 938-940
37. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, San Carlos, CA, USA